APA (7th ed.) Citation

Packer, M., Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Pocock, S. J., . . . Zannad, F. (2021). Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: The EMPEROR-Reduced trial. European heart journal, 42(6), 671-680. https://doi.org/10.1093/eurheartj/ehaa968

Chicago Style (17th ed.) Citation

Packer, Milton, et al. "Influence of Neprilysin Inhibition on the Efficacy and Safety of Empagliflozin in Patients with Chronic Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial." European Heart Journal 42, no. 6 (2021): 671-680. https://doi.org/10.1093/eurheartj/ehaa968.

MLA (9th ed.) Citation

Packer, Milton, et al. "Influence of Neprilysin Inhibition on the Efficacy and Safety of Empagliflozin in Patients with Chronic Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial." European Heart Journal, vol. 42, no. 6, 2021, pp. 671-680, https://doi.org/10.1093/eurheartj/ehaa968.